

FIRST REGULAR SESSION

HOUSE BILL NO. 165

93RD GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVE BRINGER.

Read 1st time January 5, 2005 and copies ordered printed.

STEPHEN S. DAVIS, Chief Clerk

0717L.011

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to salvia divinorum.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

(1) Has high potential for abuse; and

(2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

(1) The controlled substances listed in this subsection are included in Schedule I;

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl-alpha-methylfentanyl;

(b) Acetylmethadol;

(c) Allylprodine;

(d) Alphacetylmethadol;

(e) Alphameprodine;

(f) Alphamethadol;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 17 (g) Alpha-methylfentanyl;
- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxidine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacymorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;

- 53 (qq) PEPAP;
- 54 (rr) Phenadoxone;
- 55 (ss) Phenampromide;
- 56 (tt) Phenomorphan;
- 57 (uu) Phenoperidine;
- 58 (vv) Piritramide;
- 59 (ww) Proheptazine;
- 60 (xx) Properidine;
- 61 (yy) Propiram;
- 62 (zz) Racemoramide;
- 63 (aaa) Thiofentanyl;
- 64 (bbb) Tilidine;
- 65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
68 is possible within the specific chemical designation:

- 69 (a) Acetorphine;
- 70 (b) Acetyldihydrocodeine;
- 71 (c) Benzylmorphine;
- 72 (d) Codeine methylbromide;
- 73 (e) Codeine-N-Oxide;
- 74 (f) Cyprenorphine;
- 75 (g) Desomorphine;
- 76 (h) Dihydromorphine;
- 77 (i) Drotebanol;
- 78 (j) Etorphine; (except Hydrochloride Salt);
- 79 (k) Heroin;
- 80 (l) Hydromorphanol;
- 81 (m) Methyldesorphine;
- 82 (n) Methyldihydromorphine;
- 83 (o) Morphine methylbromide;
- 84 (p) Morphine methylsulfonate;
- 85 (q) Morphine-N-Oxide;
- 86 (r) Myrophine;
- 87 (s) Nicocodeine;
- 88 (t) Nicomorphine;

- 89 (u) Normorphine;
90 (v) Pholcodine;
91 (w) Thebacon;
92 (4) Any material, compound, mixture or preparation which contains any quantity of the
93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
95 the specific chemical designation:
96 (a) 4-bromo-2,5-dimethoxyamphetamine;
97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
98 (c) 2,5-dimethoxyamphetamine;
99 (d) 2,5-dimethoxy-4-ethylamphetamine;
100 (e) 4-methoxyamphetamine;
101 (f) 5-methoxy-3,4-methylenedioxyamphetamine;
102 (g) 4-methyl-2,5-dimethoxy amphetamine;
103 (h) 3,4-methylenedioxyamphetamine;
104 (i) 3,4-methylenedioxymethamphetamine;
105 (j) 3,4-methylenedioxy-N-ethylamphetamine;
106 (k) N-nydroxy-3, 4-methylenedioxyamphetamine;
107 (l) 3,4,5-trimethoxyamphetamine;
108 (m) Alpha-ethyltryptamine;
109 (n) Bufotenine;
110 (o) Diethyltryptamine;
111 (p) Dimethyltryptamine;
112 (q) Ibogaine;
113 (r) Lysergic acid diethylamide;
114 (s) Marijuana; (Marihuana);
115 (t) Mescaline;
116 (u) Parahexyl;
117 (v) Peyote, to include all parts of the plant presently classified botanically as *Lophophora*
118 *Williamsil Lemaire*, whether growing or not; the seeds thereof; any extract from any part of such
119 plant; and every compound, manufacture, salt, derivative, mixture or preparation of the plant,
120 its seed or extracts;
121 (w) N-ethyl-3-piperidyl benzilate;
122 (x) N-methyl-3-piperidyl benzilate;
123 (y) Psilocybin;
124 (z) Psilocyn;

- 125 (aa) Tetrahydrocannabinols;
126 (bb) Ethylamine analog of phencyclidine;
127 (cc) Pyrrolidine analog of phencyclidine;
128 (dd) Thiophene analog of phencyclidine;
129 (ee) 1-(1-(2-thienyl)cyclohexyl) pyrrolidine;
130 **(ff) *Salvia divinorum*;**
131 (5) Any material, compound, mixture or preparation containing any quantity of the
132 following substances having a depressant effect on the central nervous system, including their
133 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
134 isomers is possible within the specific chemical designation:
135 (a) Gamma hydroxybutyric acid;
136 (b) Mecloqualone;
137 (c) Methaqualone;
138 (6) Any material, compound, mixture or preparation containing any quantity of the
139 following substances having a stimulant effect on the central nervous system, including their
140 salts, isomers and salts of isomers:
141 (a) Aminorex;
142 (b) Cathinone;
143 (c) Fenethylline;
144 (d) Methcathinone;
145 (e) (+)cis-4-methylaminorex ((+)cis-4,5-dihydro- 4-methyl-5-phenyl-2-oxazoline);
146 (f) N-ethylamphetamine;
147 (g) N,N-dimethylamphetamine;
148 (7) A temporary listing of substances subject to emergency scheduling under federal law
149 shall include any material, compound, mixture or preparation which contains any quantity of the
150 following substances:
151 (a) N-(1-benzyl-4-piperidyl)-N-phenyl-propanamide (benzylfentanyl), its optical isomers,
152 salts and salts of isomers;
153 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
154 optical isomers, salts and salts of isomers.
155 3. The department of health and senior services shall place a substance in Schedule II
156 if it finds that:
157 (1) The substance has high potential for abuse;
158 (2) The substance has currently accepted medical use in treatment in the United States,
159 or currently accepted medical use with severe restrictions; and
160 (3) The abuse of the substance may lead to severe psychic or physical dependence.

161 4. The controlled substances listed in this subsection are included in Schedule II:

162 (1) Any of the following substances whether produced directly or indirectly by extraction
163 from substances of vegetable origin, or independently by means of chemical synthesis, or by
164 combination of extraction and chemical synthesis:

165 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
166 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine,
167 nalmeferene, naloxone and naltrexone, and their respective salts but including the following:

- 168 a. Raw opium;
- 169 b. Opium extracts;
- 170 c. Opium fluid;
- 171 d. Powdered opium;
- 172 e. Granulated opium;
- 173 f. Tincture of opium;
- 174 g. Codeine;
- 175 h. Ethylmorphine;
- 176 i. Etorphine hydrochloride;
- 177 j. Hydrocodone;
- 178 k. Hydromorphone;
- 179 l. Metopon;
- 180 m. Morphine;
- 181 n. Oxycodone;
- 182 o. Oxymorphone;
- 183 p. Thebaine;

184 (b) Any salt, compound, derivative, or preparation thereof which is chemically
185 equivalent or identical with any of the substances referred to in this subdivision, but not
186 including the isoquinoline alkaloids of opium;

187 (c) Opium poppy and poppy straw;

188 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
189 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
190 with any of these substances, but not including decocainized coca leaves or extractions which
191 do not contain cocaine or ecgonine;

192 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
193 or powder form which contains the phenanthrene alkaloids of the opium poppy);

194 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
195 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
196 the specific chemical designation, dextrophan and levopropoxyphene excepted:

- 197 (a) Alfentanil;
198 (b) Alphaprodine;
199 (c) Anileridine;
200 (d) Bezitramide;
201 (e) Bulk Dextropropoxyphene;
202 (f) Carfentanil;
203 (g) Butyl nitrite;
204 (h) Dihydrocodeine;
205 (i) Diphenoxylate;
206 (j) Fentanyl;
207 (k) Isomethadone;
208 (l) Levo-alphacetylmethadol;
209 (m) Levomethorphan;
210 (n) Levorphanol;
211 (o) Metazocine;
212 (p) Methadone;
213 (q) Meperidine;
214 (r) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
215 (s) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic
216 acid;
217 (t) Pethidine;
218 (u) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
219 (v) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
220 (w) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
221 (x) Phenazocine;
222 (y) Piminodine;
223 (z) Racemethorphan;
224 (aa) Racemorphan;
225 (bb) Sulfentanil;
226 (3) Any material, compound, mixture, or preparation which contains any quantity of the
227 following substances having a stimulant effect on the central nervous system:
228 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
229 (b) Methamphetamine, its salts, isomers, and salts of its isomers;
230 (c) Phenmetrazine and its salts;
231 (d) Methylphenidate;
232 (4) Any material, compound, mixture, or preparation which contains any quantity of the

233 following substances having a depressant effect on the central nervous system, including its salts,
234 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
235 is possible within the specific chemical designation:

236 (a) Amobarbital;
237 (b) Glutethimide;
238 (c) Pentobarbital;
239 (d) Phencyclidine;
240 (e) Secobarbital;
241 (5) Any material, compound or compound which contains any quantity of the following
242 substances:

243 (a) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
244 United States Food and Drug Administration approved drug product;

245 (b) Nabilone;
246 (6) Any material, compound, mixture, or preparation which contains any quantity of the
247 following substances:

248 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;

249 (b) Immediate precursors to phencyclidine (PCP):

250 a. 1-phenylcyclohexylamine;

251 b. 1-piperidinocyclohexanecarbonitrile (PCC).

252 5. The department of health and senior services shall place a substance in Schedule III
253 if it finds that:

254 (1) The substance has a potential for abuse less than the substances listed in Schedules
255 I and II;

256 (2) The substance has currently accepted medical use in treatment in the United States;
257 and

258 (3) Abuse of the substance may lead to moderate or low physical dependence or high
259 psychological dependence.

260 6. The controlled substances listed in this subsection are included in Schedule III:

261 (1) Any material, compound, mixture, or preparation which contains any quantity of the
262 following substances having a potential for abuse associated with a stimulant effect on the
263 central nervous system:

264 (a) Benzphetamine;

265 (b) Chlorphentermine;

266 (c) Clortermine;

267 (d) Phendimetrazine;

268 (2) Any material, compound, mixture or preparation which contains any quantity or salt

269 of the following substances or salts having a depressant effect on the central nervous system:
270 (a) Any material, compound, mixture or preparation which contains any quantity or salt
271 of the following substances combined with one or more active medicinal ingredients:
272 a. Amobarbital;
273 b. Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
274 a drug product for which an application has been approved under Section 505 of the Federal
275 Food, Drug, and Cosmetic Act;
276 c. Secobarbital;
277 d. Pentobarbital;
278 (b) Any suppository dosage form containing any quantity or salt of the following:
279 a. Amobarbital;
280 b. Secobarbital;
281 c. Pentobarbital;
282 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
283 salt;
284 (d) Chlorhexadol;
285 (e) Ketamine, its salts, isomers, and salts of isomers;
286 (f) Lysergic acid;
287 (g) Lysergic acid amide;
288 (h) Methyprylon;
289 (i) Sulfondiethylmethane;
290 (j) Sulfonethylmethane;
291 (k) Sulfonmethane;
292 (l) Tiletamine and zolazepam or any salt thereof;
293 (3) Nalorphine;
294 (4) Any material, compound, mixture, or preparation containing limited quantities of any
295 of the following narcotic drugs or their salts:
296 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
297 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
298 of opium;
299 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
300 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
301 therapeutic amounts;
302 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
303 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
304 isoquinoline alkaloid of opium;

305 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
306 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
307 ingredients in recognized therapeutic amounts;

308 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or more than
309 ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized
310 therapeutic amounts;

311 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
312 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
313 ingredients in recognized therapeutic amounts;

314 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per
315 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
316 active nonnarcotic ingredients in recognized therapeutic amounts;

317 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
318 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
319 amounts;

320 (5) Anabolic steroids. Unless specially excepted or unless listed in another schedule, any
321 material, compound, mixture or preparation containing any quantity of the following substances,
322 including its salts, isomers and salts of isomers whenever the existence of such salts of isomers
323 is possible within the specific chemical designation:

324 (a) Boldenone;

325 (b) Chlorotestosterone (4-Chlortestosterone);

326 (c) Clostebol;

327 (d) Dehydrochlormethyltestosterone;

328 (e) Dihydrotestosterone (4-Dihydro-testosterone);

329 (f) Drostanolone;

330 (g) Ethylestrenol;

331 (h) Fluoxymesterone;

332 (i) Formebolone (Formebolone);

333 (j) Mesterolone;

334 (k) Methandienone;

335 (l) Methandranone;

336 (m) Methandriol;

337 (n) Methandrostenolone;

338 (o) Methenolone;

339 (p) Methyltestosterone;

340 (q) Mibolerone;

341 (r) Nandrolone;
342 (s) Norethandrolone;
343 (t) Oxandrolone;
344 (u) Oxymesterone;
345 (v) Oxymetholone;
346 (w) Stanolone;
347 (x) Stanozolol;
348 (y) Testolactone;
349 (z) Testosterone;
350 (aa) Trenbolone;
351 (bb) Any salt, ester, or isomer of a drug or substance described or listed in this
352 subdivision, if that salt, ester or isomer promotes muscle growth except an anabolic steroid
353 which is expressly intended for administration through implants to cattle or other nonhuman
354 species and which has been approved by the secretary of health and human services for that
355 administration.

356 (6) The department of health and senior services may except by rule any compound,
357 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
358 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to
359 195.320 if the compound, mixture, or preparation contains one or more active medicinal
360 ingredients not having a stimulant or depressant effect on the central nervous system, and if the
361 admixtures are included therein in combinations, quantity, proportion, or concentration that
362 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
363 the central nervous system.

364 7. The department of health and senior services shall place a substance in Schedule IV
365 if it finds that:

366 (1) The substance has a low potential for abuse relative to substances in Schedule III;
367 (2) The substance has currently accepted medical use in treatment in the United States;
368 and

369 (3) Abuse of the substance may lead to limited physical dependence or psychological
370 dependence relative to the substances in Schedule III.

371 8. The controlled substances listed in this subsection are included in Schedule IV:

372 (1) Any material, compound, mixture, or preparation containing any of the following
373 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
374 as set forth below:

375 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
376 of atropine sulfate per dosage unit;

377 (b) Dextropropoxyphene (alpha-(+)-4-dimethy-lamino-1, 2-diphenyl-3-methyl-2-
378 propionoxybutane);

379 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
380 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
381 upon the compound, mixture or preparation valuable medicinal qualities other than those
382 possessed by the narcotic drug alone:

383 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
384 one hundred grams;

385 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
386 or per one hundred grams;

387 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
388 or per one hundred grams;

389 (2) Any material, compound, mixture or preparation containing any quantity of the
390 following substances, including their salts, isomers, and salts of isomers whenever the existence
391 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

392 (a) Alprazolam;

393 (b) Barbitol;

394 (c) Bromazepam;

395 (d) Camazepam;

396 (e) Chloral betaine;

397 (f) Chloral hydrate;

398 (g) Chlordiazepoxide;

399 (h) Clobazam;

400 (i) Clonazepam;

401 (j) Clorazepate;

402 (k) Clotiazepam;

403 (l) Cloxazolam;

404 (m) Delorazepam;

405 (n) Diazepam;

406 (o) Estazolam;

407 (p) Ethchlorvynol;

408 (q) Ethinamate;

409 (r) Ethyl loflazepate;

410 (s) Fludiazepam;

411 (t) Flunitrazepam;

412 (u) Flurazepam;

- 413 (v) Halazepam;
- 414 (w) Haloxazolam;
- 415 (x) Ketazolam;
- 416 (y) Loprazolam;
- 417 (z) Lorazepam;
- 418 (aa) Lormetazepam;
- 419 (bb) Mebutamate;
- 420 (cc) Medazepam;
- 421 (dd) Meprobamate;
- 422 (ee) Methohexital;
- 423 (ff) Methylphenobarbital;
- 424 (gg) Midazolam;
- 425 (hh) Nimetazepam;
- 426 (ii) Nitrazepam;
- 427 (jj) Nordiazepam;
- 428 (kk) Oxazepam;
- 429 (ll) Oxazolam;
- 430 (mm) Paraldehyde;
- 431 (nn) Petrichloral;
- 432 (oo) Phenobarbital;
- 433 (pp) Pinazepam;
- 434 (qq) Prazepam;
- 435 (rr) Quazepam;
- 436 (ss) Temazepam;
- 437 (tt) Tetrazepam;
- 438 (uu) Triazolam;
- 439 (vv) Zolpidem;
- 440 (3) Any material, compound, mixture, or preparation which contains any quantity of the
- 441 following substance including its salts, isomers and salts of isomers whenever the existence of
- 442 such salts, isomers and salts of isomers is possible: fenfluramine;
- 443 (4) Any material, compound, mixture or preparation containing any quantity of the
- 444 following substances having a stimulant effect on the central nervous system, including their
- 445 salts, isomers and salts of isomers:
- 446 (a) Cathine ((+)-norpseudoephedrine);
- 447 (b) Diethylpropion;
- 448 (c) Fencamfamin;

- 449 (d) Fenproporex;
450 (e) Mazindol;
451 (f) Mefenorex;
452 (g) Pemoline, including organometallic complexes and chelates thereof;
453 (h) Phentermine;
454 (i) Pipradrol;
455 (j) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
456 (5) Any material, compound, mixture or preparation containing any quantity of the
457 following substance, including its salts: pentazocine;
458 (6) Any material, compound, mixture or preparation which contains any quantity of the
459 following substances having a stimulant effect on the central nervous system including their
460 salts, isomers and salts of isomers: ephedrine or its salts, optical isomers, or salts of optical
461 isomers as the only active medicinal ingredient or contains ephedrine or its salts, optical isomers,
462 or salts of optical isomers and therapeutically insignificant quantities of another active medicinal
463 ingredient;
464 (7) The department of health and senior services may except by rule any compound,
465 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
466 subsection from the application of all or any part of sections 195.010 to 195.320 if the
467 compound, mixture, or preparation contains one or more active medicinal ingredients not having
468 a depressant effect on the central nervous system, and if the admixtures are included therein in
469 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
470 substances which have a depressant effect on the central nervous system.
471 9. The department of health and senior services shall place a substance in Schedule V
472 if it finds that:
473 (1) The substance has low potential for abuse relative to the controlled substances listed
474 in Schedule IV;
475 (2) The substance has currently accepted medical use in treatment in the United States;
476 and
477 (3) The substance has limited physical dependence or psychological dependence liability
478 relative to the controlled substances listed in Schedule IV.
479 10. The controlled substances listed in this subsection are included in Schedule V:
480 (1) Any material, compound, mixture or preparation containing any of the following
481 narcotic drug and its salts: buprenorphine;
482 (2) Any compound, mixture or preparation containing any of the following narcotic
483 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set
484 forth below, which also contains one or more nonnarcotic active medicinal ingredients in

485 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
486 qualities other than those possessed by the narcotic drug alone:

487 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
488 twenty-five micrograms of atropine sulfate per dosage unit;

489 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per
490 one hundred grams;

491 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
492 micrograms of atropine sulfate per dosage unit;

493 (3) Any material, compound, mixture or preparation which contains any quantity of the
494 following substance having a stimulant effect on the central nervous system including its salts,
495 isomers and salts of isomers: pyrovalerone.

496 11. The department of health and senior services shall revise and republish the schedules
497 annually.